S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:IRMD

Iradimed (IRMD) Stock Price, News & Analysis

$43.99
+0.62 (+1.43%)
(As of 03/28/2024 ET)
Today's Range
$43.15
$44.64
50-Day Range
$41.17
$46.76
52-Week Range
$36.12
$51.04
Volume
64,163 shs
Average Volume
56,165 shs
Market Capitalization
$556.91 million
P/E Ratio
32.35
Dividend Yield
1.36%
Price Target
$60.00

Iradimed MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36.4% Upside
$60.00 Price Target
Short Interest
Healthy
1.42% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.44mentions of Iradimed in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.82 out of 5 stars

Medical Sector

35th out of 938 stocks

Surgical & Medical Instruments Industry

6th out of 97 stocks

IRMD stock logo

About Iradimed Stock (NASDAQ:IRMD)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

IRMD Stock Price History

IRMD Stock News Headlines

IRadimed Co. (NASDAQ:IRMD) Short Interest Up 5.7% in February
IRMD Jul 2024 60.000 call
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
iRadimed Corp.
Should You Invest in IRadimed Corporation (IRMD)?
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
IRMD Mar 2024 45.000 put
IRMD Mar 2024 40.000 call
IRMD Feb 2024 44.520 call
IRadimed: Q4 Earnings Snapshot
iRadimed's Earnings Outlook
iRadimed Q4 2023 Earnings Preview
Lake Street Reaffirms Their Buy Rating on Iradimed (IRMD)
See More Headlines
Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iradimed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/12 Dividend
12/21/2023
Dividend Payable
1/12/2024
Last Earnings
2/08/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:IRMD
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.00
High Stock Price Target
$60.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+36.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$17.19 million
Pretax Margin
33.16%

Debt

Sales & Book Value

Annual Sales
$65.56 million
Cash Flow
$1.47 per share
Book Value
$5.66 per share

Miscellaneous

Free Float
7,269,000
Market Cap
$556.91 million
Optionable
Optionable
Beta
0.82
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Roger E. Susi (Age 71)
    Founder, Chairman, CEO & President
    Comp: $586.04k
  • Mr. John F. Glenn (Age 62)
    CFO & Corporate Secretary
    Comp: $411.79k
  • Mr. Randy Waddell
    Vice President of Worldwide Sales & Marketing
  • Mr. Steve Kachelmeyer
    Vice President of Regulatory Affairs & Quality Assurance
  • Mr. Lynn Neuhardt
    Vice President of Research & Development
  • Mr. Chris Williamson
    Executive Vice President of Continuous Improvement & Information Technology
  • Mr. Matt Garner
    Controller

IRMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Iradimed stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRMD shares.
View IRMD analyst ratings
or view top-rated stocks.

What is Iradimed's stock price target for 2024?

1 analysts have issued 12 month target prices for Iradimed's stock. Their IRMD share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 36.4% from the stock's current price.
View analysts price targets for IRMD
or view top-rated stocks among Wall Street analysts.

How have IRMD shares performed in 2024?

Iradimed's stock was trading at $47.47 at the beginning of the year. Since then, IRMD shares have decreased by 7.3% and is now trading at $43.99.
View the best growth stocks for 2024 here
.

Are investors shorting Iradimed?

Iradimed saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 112,900 shares, an increase of 11.0% from the February 29th total of 101,700 shares. Based on an average daily volume of 54,200 shares, the days-to-cover ratio is currently 2.1 days. Approximately 1.4% of the shares of the company are sold short.
View Iradimed's Short Interest
.

When is Iradimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our IRMD earnings forecast
.

How were Iradimed's earnings last quarter?

Iradimed Corporation (NASDAQ:IRMD) announced its earnings results on Thursday, February, 8th. The medical equipment provider reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.37 by $0.01. The medical equipment provider earned $17.45 million during the quarter. Iradimed had a net margin of 26.22% and a trailing twelve-month return on equity of 24.62%.

How often does Iradimed pay dividends? What is the dividend yield for Iradimed?

Iradimed announced a -- dividend on Tuesday, December 12th. Investors of record on Friday, December 22nd will be given a dividend of $0.15 per share on Friday, January 12th. The ex-dividend date of this dividend is Thursday, December 21st.
Read our dividend analysis for IRMD
.

Is Iradimed a good dividend stock?

Iradimed (NASDAQ:IRMD) pays an annual dividend of $0.60 per share and currently has a dividend yield of 1.41%. The dividend payout ratio is 44.12%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for IRMD.

What ETF holds Iradimed's stock?

Ballast Small/Mid Cap ETF holds 19,404 shares of IRMD stock, representing 0.98% of its portfolio.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed issued an update on its first quarter 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 0.330-0.350 for the period, compared to the consensus estimate of 0.410. The company issued revenue guidance of $17.0 million-$17.3 million, compared to the consensus revenue estimate of $17.6 million.

What other stocks do shareholders of Iradimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).

Who are Iradimed's major shareholders?

Iradimed's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.39%), Vanguard Group Inc. (3.37%), RK Capital Management LLC (2.70%), Ranger Investment Management L.P. (1.77%), Russell Investments Group Ltd. (1.68%) and Dimensional Fund Advisors LP (1.67%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi.
View institutional ownership trends
.

How do I buy shares of Iradimed?

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRMD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners